Expanding Role of Gastroenterologists in Acute Gastrointestinal Graft-versus-Host Disease: From Diagnosis and Management to Microbiome-Based Strategies
Author:
Open Access
- 25 July 2025
- journal article
- abstracts
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 85 (3) , 268-273
Abstract
Acute graft-versus-host disease (GVHD) is a major complication following allogeneic hematopoietic stem cell transplantation. Steroid-refractory cases have poor outcomes, so an accurate diagnosis, particularly differentiation from cytomegalovirus colitis, is critical. Ruxolitinib is the standard second-line therapy, while Vedolizumab has shown potential in gut-specific modulation. Recent studies have reported that reduced microbiome diversity and the loss of short-chain fatty acid-producing bacteria are linked to acute GVHD severity and mortality. Fecal microbiota transplantation may offer benefit in selected steroid-refractory cases, but the evidence remains limited and variable. Gastroenterologists play an essential role in diagnosis and microbiome-guided care. A personalized approach incorporating microbial biomarkers may improve the future outcomes.Keywords
This publication has 26 references indexed in Scilit:
- Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant diseaseAnnals of Hematology, 2024
- Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program RegistryTransplantation and Cellular Therapy, 2024
- Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experienceInternational Journal of Hematology, 2022
- GVHD, IBD, and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunityEuropean Journal of Immunology, 2022
- Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host DiseaseTransplantation and Cellular Therapy, 2021
- Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter studyAmerican Journal of Hematology, 2020
- Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record ReviewTransplantation and Cellular Therapy, 2019
- Gut microbiota injury in allogeneic haematopoietic stem cell transplantationNature Reviews Cancer, 2018
- Acute graft-versus-host disease of the gut: considerations for the gastroenterologistNature Reviews Gastroenterology & Hepatology, 2017
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016